Use

Mycophenolate mofetil (CellCept) is an immunosuppressive agent beneficial in organ transplantation, approved for use in renal, hepatic, and cardiac transplants. Once in the bloodstream, it converts to the active form, mycophenolic acid (MPA), which selectively inhibits the de novo pathway of guanosine nucleotide synthesis in lymphocytes, curtailing T and B lymphocyte proliferation. Monitoring the blood levels of MPA and its metabolite, MPA glucuronide (MPA-G), is crucial to customize therapy and prevent excessive immunosuppression, which can predispose patients to systemic infections. Adjustments are often required before and after changes in immunosuppressive therapy or when significant changes in health status occur.